We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

ASH 2013

Idelalisib/Rituximab Combo Improves Survival in Late-Stage CLL

  • Anna Azvolinsky
Dec 11, 2013

A phase III trial of idelalisib plus rituximab in patients with previously treated chronic lymphocytic leukemia found that the combo improved progression-free and overall survival, according to results presented at the 2013 ASH meeting.

In Therapy-Related AML, p53 Mutations Already Exist

  • Anna Azvolinsky
Dec 11, 2013

In a study presented at the 2013 ASH meeting, researchers showed evidence that p53 mutations are already present in patients who develop treatment-related MDS and AML, results which could help identify high-risk patients prior to cytotoxic therapy.

In Pediatric AML, CD33 Targeting Agent Improved EFS, Risk of Relapse

  • Leah Lawrence
Dec 11, 2013

Treatment with gemtuzumab ozogamicin improved the event-free survival in children and adolescents with acute myeloid leukemia by reducing the risk of relapse among those able to achieve remission, according to trial results presented at the 2013 ASH meeting.

Immunotherapy Prior to Stem Cell Transplant in Multiple Myeloma

  • Lawrence G. Lum, MD, DSc
Dec 11, 2013

In a 12-patient multiple myeloma pilot study, researchers demonstrated that anti-CD3 and anti-CD20 bispecific antibody (CD20Bi) activated both cellular and humoral anti-myeloma immunity that was detectable after patients received an autologous stem cell transplant.

New Mutation Identified in Primary Myelofibrosis Patients

  • Thorsten Klampfl, PhD
Dec 10, 2013

In a late-breaking abstract presentation, Thorsten Klampfl, PhD, of the CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, presented data from a whole exome study of primary myelofibrosis patients, identifying a new specific molecular mutation

New Therapies in Development for Multiple Myeloma

  • Joseph R. Mikhael, MD
Dec 10, 2013

In this video, Dr. Mikhael discusses the current treatment paradigm for multiple myeloma and highlights some of the new agents in development.

Siltuximab New Treatment Option for Multicentric Castleman Disease

  • Leah Lawrence
Dec 10, 2013

Patients with the rare and potentially deadly multicentric Castleman disease were able to achieve durable tumor and symptomatic response when assigned to treatment with the monoclonal antibody siltuximab, according to data presented at the 2013 ASH meeting.

Front-Line Combo for Multiple Myeloma Shows Survival Benefit

  • Anna Azvolinsky
Dec 10, 2013

The combination of lenalidomide plus dexamethasone demonstrated an improvement in both response rate and survival in newly diagnosed multiple myeloma patients not eligible for a stem cell transplant, according to data presented at the 2013 ASH meeting.

Age Not a Barrier to Half-Matched Bone Marrow Transplants

  • Leah Lawrence
Dec 10, 2013

Patients aged 70 years or older had similar survival outcomes compared to their younger counterparts when undergoing nonmyeloablative, related haploidentical bone marrow or peripheral blood stem cell transplants for the treatment of hematologic malignancies, according to the results of a study presented at the 2013 ASH meeting.

Obinutuzumab Tops Rituximab in CLL Trial

  • Anna Azvolinsky
Dec 9, 2013

In a front-line trial of older patients with newly diagnosed chronic lymphocytic leukemia, obinutuzumab topped rituximab, demonstrating improvements in response rate and progression-free survival, according to results presented at the ASH annual meeting.

Pages

  • 1
  • 2
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.